Epithelial Ovarian Cancer - Pipeline Review, H2 2016

 

Rating

4.9 Star Rating for report Epithelial Ovarian Cancer - Pipeline Review, H2 2016
4.9 / 5 stars rating
Pages: 507
Price: $2000.00

Some of our Clients

Some Research and Expert Clients

Abstract

 
Ovarian epithelial cancer is a disease in which malignant (cancer) cells form in the tissue covering the ovary. Early ovarian cancer may not cause any symptoms. When symptoms do appear, ovarian cancer is often advanced. Symptoms may include pain or swelling in the abdomen, pain in the pelvis and gastrointestinal problems, such as gas, bloating, or constipation. There are different types of treatment for patients with ovarian epithelial cancer such as surgery, radiation therapy, and chemotherapy.  

Description

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Epithelial Ovarian Cancer - Pipeline Review, H2 2016, provides an overview of the Epithelial Ovarian Cancer (Oncology) pipeline landscape.

Ovarian epithelial cancer is a disease in which malignant (cancer) cells form in the tissue covering the ovary. Early ovarian cancer may not cause any symptoms. When symptoms do appear, ovarian cancer is often advanced. Symptoms may include pain or swelling in the abdomen, pain in the pelvis and gastrointestinal problems, such as gas, bloating, or constipation. There are different types of treatment for patients with ovarian epithelial cancer such as surgery, radiation therapy, and chemotherapy.
 

Similar Reports

Other reports that may be of interest...

Report... 05IB-GMDHC8870IDBColorectal Cancer - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8862IDBPancreatic Cancer - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8864IDBNon-Small Cell Lung Cancer - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8866IDBOvarian Cancer - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8868IDBMelanoma - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8869IDBAcute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - P...Dec 2016
Report... 05IB-GMDHC8871IDBBreast Cancer - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8860IDBProstate Cancer - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8844IDBMultiple Myeloma (Kahler Disease) - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8816IDBKidney Cancer (Renal Cell Cancer) - Pipeline Review, H2 2016Dec 2016

Report Source Information

Supplied by: Research and Experts 
Date Published: 2016-11-30 

Report: Epithelial Ovarian Cancer - Pipeline Review, H2 2016

 

Contents

Table of Contents
Table of Contents 2
Introduction 6
Epithelial Ovarian Cancer Overview 7
Therapeutics Development 8
Epithelial Ovarian Cancer - Therapeutics under Development by Companies 10
Epithelial Ovarian Cancer - Therapeutics under Investigation by Universities/Institutes 15
Epithelial Ovarian Cancer - Pipeline Products Glance 16
Epithelial Ovarian Cancer - Products under Development by Companies 20
Epithelial Ovarian Cancer - Products under Investigation by Universities/Institutes 26
Epithelial Ovarian Cancer - Companies Involved in Therapeutics Development 27
Epithelial Ovarian Cancer - Therapeutics Assessment 94
Drug Profiles 115
Epithelial Ovarian Cancer - Dormant Projects 480
Epithelial Ovarian Cancer - Discontinued Products 484
Epithelial Ovarian Cancer - Product Development Milestones 485
Appendix 495
 

List of Tables

List of Tables
Number of Products under Development for Epithelial Ovarian Cancer, H2 2016 19
Number of Products under Development for Epithelial Ovarian Cancer - Comparative Analysis, H2 2016 20
Number of Products under Development by Companies, H2 2016 21
Number of Products under Development by Companies, H2 2016 (Contd..1) 22
Number of Products under Development by Companies, H2 2016 (Contd..2) 23
Number of Products under Development by Companies, H2 2016 (Contd..3) 24
Number of Products under Development by Companies, H2 2016 (Contd..4) 25
Number of Products under Investigation by Universities/Institutes, H2 2016 26
Comparative Analysis by Late Stage Development, H2 2016 27
Comparative Analysis by Clinical Stage Development, H2 2016 28
Comparative Analysis by Early Stage Development, H2 2016 29
Comparative Analysis by Unknown Stage Development, H2 2016 30
Products under Development by Companies, H2 2016 31
Products under Development by Companies, H2 2016 (Contd..1) 32
Products under Development by Companies, H2 2016 (Contd..2) 33
Products under Development by Companies, H2 2016 (Contd..3) 34
Products under Development by Companies, H2 2016 (Contd..4) 35
Products under Development by Companies, H2 2016 (Contd..5) 36
Products under Investigation by Universities/Institutes, H2 2016 37
Epithelial Ovarian Cancer - Pipeline by AbbVie Inc, H2 2016 38
Epithelial Ovarian Cancer - Pipeline by Adaptimmune Therapeutics Plc, H2 2016 39
Epithelial Ovarian Cancer - Pipeline by Amgen Inc, H2 2016 40
Epithelial Ovarian Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2016 41
Epithelial Ovarian Cancer - Pipeline by AstraZeneca Plc, H2 2016 42
Epithelial Ovarian Cancer - Pipeline by Atara Biotherapeutics Inc, H2 2016 43
Epithelial Ovarian Cancer - Pipeline by Bayer AG, H2 2016 44
Epithelial Ovarian Cancer - Pipeline by BioNumerik Pharmaceuticals Inc, H2 2016 45
Epithelial Ovarian Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016 46
Epithelial Ovarian Cancer - Pipeline by Boston Biomedical Inc, H2 2016 47
Epithelial Ovarian Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2016 48
Epithelial Ovarian Cancer - Pipeline by Celldex Therapeutics Inc, H2 2016 49
Epithelial Ovarian Cancer - Pipeline by Celon Pharma Sp z oo, H2 2016 50
Epithelial Ovarian Cancer - Pipeline by Celsion Corp, H2 2016 51
Epithelial Ovarian Cancer - Pipeline by CerRx Inc, H2 2016 52
Epithelial Ovarian Cancer - Pipeline by Cerulean Pharma Inc, H2 2016 53
Epithelial Ovarian Cancer - Pipeline by Clovis Oncology Inc, H2 2016 54
Epithelial Ovarian Cancer - Pipeline by Dr. Reddy's Laboratories Ltd, H2 2016 55
Epithelial Ovarian Cancer - Pipeline by EirGenix Inc., H2 2016 56
Epithelial Ovarian Cancer - Pipeline by Eisai Co Ltd, H2 2016 57
Epithelial Ovarian Cancer - Pipeline by Eli Lilly and Company, H2 2016 58
Epithelial Ovarian Cancer - Pipeline by Esperance Pharmaceuticals Inc, H2 2016 59
Epithelial Ovarian Cancer - Pipeline by Exelixis Inc, H2 2016 60
Epithelial Ovarian Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 61
Epithelial Ovarian Cancer - Pipeline by Gene Techno Science Co Ltd, H2 2016 62
Epithelial Ovarian Cancer - Pipeline by Genentech Inc, H2 2016 63
Epithelial Ovarian Cancer - Pipeline by Genor BioPharma Co Ltd, H2 2016 64
Epithelial Ovarian Cancer - Pipeline by Glycotope GmbH, H2 2016 65
Epithelial Ovarian Cancer - Pipeline by Ignyta Inc, H2 2016 66
Epithelial Ovarian Cancer - Pipeline by ImmunoGen Inc, H2 2016 67
Epithelial Ovarian Cancer - Pipeline by Incyte Corp, H2 2016 68
Epithelial Ovarian Cancer - Pipeline by Innate Immunotherapeutics Ltd, H2 2016 69
Epithelial Ovarian Cancer - Pipeline by Johnson & Johnson, H2 2016 70
Epithelial Ovarian Cancer - Pipeline by Juno Therapeutics Inc, H2 2016 71
Epithelial Ovarian Cancer - Pipeline by Mabion SA, H2 2016 72
Epithelial Ovarian Cancer - Pipeline by MabVax Therapeutics Holdings Inc, H2 2016 73
Epithelial Ovarian Cancer - Pipeline by Mateon Therapeutics Inc, H2 2016 74
Epithelial Ovarian Cancer - Pipeline by MedImmune LLC, H2 2016 75
Epithelial Ovarian Cancer - Pipeline by Merck & Co Inc, H2 2016 76
Epithelial Ovarian Cancer - Pipeline by Merck KGaA, H2 2016 77
Epithelial Ovarian Cancer - Pipeline by Mycenax Biotech Inc, H2 2016 78
Epithelial Ovarian Cancer - Pipeline by Novartis AG, H2 2016 79
Epithelial Ovarian Cancer - Pipeline by Novogen Ltd, H2 2016 80
Epithelial Ovarian Cancer - Pipeline by Oasmia Pharmaceutical AB, H2 2016 81
Epithelial Ovarian Cancer - Pipeline by OBI Pharma Inc, H2 2016 82
Epithelial Ovarian Cancer - Pipeline by Oncobiologics Inc, H2 2016 83
Epithelial Ovarian Cancer - Pipeline by Oncolix Inc, H2 2016 84
Epithelial Ovarian Cancer - Pipeline by Oncolytics Biotech Inc, H2 2016 85
Epithelial Ovarian Cancer - Pipeline by Oxford BioMedica Plc, H2 2016 86
Epithelial Ovarian Cancer - Pipeline by OXIS International, Inc., H2 2016 87
Epithelial Ovarian Cancer - Pipeline by Pharma Mar SA, H2 2016 88
Epithelial Ovarian Cancer - Pipeline by Prima BioMed Ltd, H2 2016 89
Epithelial Ovarian Cancer - Pipeline by PsiOxus Therapeutics Ltd, H2 2016 90
Epithelial Ovarian Cancer - Pipeline by Rgenix Inc, H2 2016 91
Epithelial Ovarian Cancer - Pipeline by Richter Gedeon Nyrt, H2 2016 92
Epithelial Ovarian Cancer - Pipeline by Sanofi, H2 2016 93
Epithelial Ovarian Cancer - Pipeline by Sanofi Pasteur SA, H2 2016 94
Epithelial Ovarian Cancer - Pipeline by Shenzen SiBiono GeneTech Co., Ltd., H2 2016 95
Epithelial Ovarian Cancer - Pipeline by Sotio as, H2 2016 96
Epithelial Ovarian Cancer - Pipeline by TapImmune Inc, H2 2016 97
Epithelial Ovarian Cancer - Pipeline by Tara Immuno-Oncology Therapeutics LLC, H2 2016 98
Epithelial Ovarian Cancer - Pipeline by Tesaro Inc, H2 2016 99
Epithelial Ovarian Cancer - Pipeline by TetraLogic Pharmaceuticals, H2 2016 100
Epithelial Ovarian Cancer - Pipeline by Tyrogenex Inc, H2 2016 101
Epithelial Ovarian Cancer - Pipeline by VentiRx Pharmaceuticals Inc, H2 2016 102
Epithelial Ovarian Cancer - Pipeline by Verastem Inc, H2 2016 103
Epithelial Ovarian Cancer - Pipeline by Vyriad Inc, H2 2016 104
Assessment by Monotherapy Products, H2 2016 105
Number of Products by Stage and Target, H2 2016 107
Number of Products by Stage and Mechanism of Action, H2 2016 115
Number of Products by Stage and Route of Administration, H2 2016 123
Number of Products by Stage and Molecule Type, H2 2016 125
Epithelial Ovarian Cancer - Dormant Projects, H2 2016 491
Epithelial Ovarian Cancer - Dormant Projects (Contd..1), H2 2016 492
Epithelial Ovarian Cancer - Dormant Projects (Contd..2), H2 2016 493
Epithelial Ovarian Cancer - Dormant Projects (Contd..3), H2 2016 494
Epithelial Ovarian Cancer - Discontinued Products, H2 2016 495
 

List of Figures

List of Figures
Number of Products under Development for Epithelial Ovarian Cancer, H2 2016 19
Number of Products under Development for Epithelial Ovarian Cancer - Comparative Analysis, H2 2016 20
Number of Products under Development by Companies, H2 2016 21
Number of Products under Investigation by Universities/Institutes, H2 2016 26
Comparative Analysis by Late Stage Development, H2 2016 27
Comparative Analysis by Clinical Stage Development, H2 2016 28
Comparative Analysis by Early Stage Products, H2 2016 29
Assessment by Monotherapy Products, H2 2016 105
Number of Products by Top 10 Targets, H2 2016 106
Number of Products by Stage and Top 10 Targets, H2 2016 106
Number of Products by Top 10 Mechanism of Actions, H2 2016 114
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 114
Number of Products by Top 10 Routes of Administration, H2 2016 122
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 122
Number of Products by Top 10 Molecule Types, H2 2016 124
Number of Products by Stage and Top 10 Molecule Types, H2 2016 124
 

Scope


- The pipeline guide provides a snapshot of the global therapeutic landscape of Epithelial Ovarian Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Epithelial Ovarian Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Epithelial Ovarian Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Epithelial Ovarian Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Epithelial Ovarian Cancer (Oncology)

 

Highlights

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Epithelial Ovarian Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Epithelial Ovarian Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Epithelial Ovarian Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Epithelial Ovarian Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 11, 38, 23, 2, 11, 2 and 1 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 3 and 3 molecules, respectively.Epithelial Ovarian Cancer.

Epithelial Ovarian Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

 

Classification

Language Code: EN 
Region: Global 
Report Type: Market Report 
Industry: Life Sciences 
Sector: Oncology 
Pages: 507 

Companies Featured

AbbVie Inc Adaptimmune Therapeutics Plc Amgen Inc Astex Pharmaceuticals Inc AstraZeneca Plc Atara Biotherapeutics Inc Bayer AG BioNumerik Pharmaceuticals Inc Boehringer Ingelheim GmbH Boston Biomedical Inc Bristol-Myers Squibb Company Celldex Therapeutics Inc Celon Pharma Sp z oo Celsion Corp CerRx Inc Cerulean Pharma Inc Clovis Oncology Inc Dr. Reddy's Laboratories Ltd EirGenix Inc. Eisai Co Ltd Eli Lilly and Company Esperance Pharmaceuticals Inc Exelixis Inc F. Hoffmann-La Roche Ltd Gene Techno Science Co Ltd Genentech Inc Genor BioPharma Co Ltd Glycotope GmbH Ignyta Inc ImmunoGen Inc Incyte Corp Innate Immunotherapeutics Ltd Johnson & Johnson Juno Therapeutics Inc Mabion SA MabVax Therapeutics Holdings Inc Mateon Therapeutics Inc MedImmune LLC Merck & Co Inc Merck KGaA Mycenax Biotech Inc Novartis AG Novogen Ltd Oasmia Pharmaceutical AB OBI Pharma Inc Oncobiologics Inc Oncolix Inc Oncolytics Biotech Inc Oxford BioMedica Plc OXIS International, Inc. Pharma Mar SA Prima BioMed Ltd PsiOxus Therapeutics Ltd Rgenix Inc Richter Gedeon Nyrt Sanofi Sanofi Pasteur SA Shenzen SiBiono GeneTech Co., Ltd. Sotio as TapImmune Inc Tara Immuno-Oncology Therapeutics LLC Tesaro Inc TetraLogic Pharmaceuticals Tyrogenex Inc VentiRx Pharmaceuticals Inc Verastem Inc Vyriad Inc

 

Reasons to buy this report


- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Epithelial Ovarian Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Epithelial Ovarian Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 

Similar Reports

Other reports that may be of interest...

Report... 05IB-GMDHC8870IDBColorectal Cancer - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8862IDBPancreatic Cancer - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8864IDBNon-Small Cell Lung Cancer - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8866IDBOvarian Cancer - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8868IDBMelanoma - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8869IDBAcute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - P...Dec 2016
Report... 05IB-GMDHC8871IDBBreast Cancer - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8860IDBProstate Cancer - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8844IDBMultiple Myeloma (Kahler Disease) - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8816IDBKidney Cancer (Renal Cell Cancer) - Pipeline Review, H2 2016Dec 2016

Epithelial Ovarian Cancer - Pipeline Review, H2 2016

Report 05IB-GMDHC8712IDB has a rating of 97 percent
Figure of merit assessment for report 05IB-GMDHC8712IDB

Relevance Rating

The Research and Experts relevance ranting consists of a set of figure of merit (FOM) values that are provided as an indication of the value of the report in the current economic environment.

These FOM values cannot take into account the reason for the clients interest in a report and therefore the client should view these FOM values only as a visual guide. The FOM scores are based on

market interest - how often the report is viewed or purchased,
elapsed time - time since the report was published,
report detail - amount of detail in the report (pages, figures, images, comments etc.) and
price - the price of the report.


Regional Information

Taxonomy

Branch ID: 1591

Taxonomy Location

The taxonomy on the left shows the ancestors of the Global node. This provides an insight into parent categories that may provide reports or articles that may compliment this report. The number in brackets after the node name indicates the number of reports that Research and Experts currently have in the parent category.

Clicking on a parent category will present the list of reports in the parent node in a separate window.

Global

The global economy is the economy of all the world's countries. The total world population now stands at over 7 billion and the global unemployment rate is 9% with approximately half the world's population paid less than $2 a day. 

The global economy is picking up again after five years of uncertaintity and slow economic growth. The IMF is predicting global growth of 3.7% in 2014 rising to 3.9% in 2015. However, much uncertainity remains. Low inflation in developed economies means that these economies take longer to deal with debt burdens and are at increases risk of deflation. 

The second half of 2013 saw growth in the US and European economies (particularly UK, Germany and France).  

Growth in the US has been helped by cheaper energy from fracking , renewables and more oil and gas exploration. This cheaper energy is bring manufacturing jobs back to the US and helping to boost domestic demand. Recent winter weather conditions have hampered growth in the construction sector and have slowed demand in the construction equipment sector which saw exports drop by 25% in 2013. Growth should pick up in this sector with continued federal investment in infrastructure, new residential house builds and refurbishment and the energy boom.

In Europe growth is expected to be uneven with growth being slow in stressed economies such as Portugal and Greece but confidence picking up in UK, Ireland and even Spain showing some improvement.

Developing economies such as China and India will continue to have strong growth in 2014 and 2015. China has benefitted from increased investment with the Chinese govenment now focused on quality growth of 7.5% in 2014. India which is less reliant on exports expects growth of 5.4% in 2014 and 6.4% in 2015.

Much uncertainity still remains in the global economy with greater optimism needed to stabilise growth.

Links

World Bank

IMF (International Monetary Fund)

 

 

Zones

Regional zones

 

Country

Countries

 

Industry Sector Information

Taxonomy

Branch ID: 7174

Taxonomy Location

The taxonomy on the left shows the ancestors of the Oncology node. This provides an insight into parent categories that may provide reports or articles that may compliment this report. The number in brackets after the node name indicates the number of reports that Research and Experts currently have in the parent category.

Clicking on a parent category will present the list of reports in the parent node in a separate window.

Oncology

Oncology

 

Healthcare

The healthcare industry is changing rapidly due to changes in legislation (US Affordable Healthcare Act),  advances in IT and more pressures on governments and healthcare providers due to rising costs. 

According to a recent report by the OECD healthcare spending has fallen in one third of OECD member states due to the credit crunch and members are facing up to the challenge of providing greater care with fewer resources. Spending on healthcare has increased in Japan, Israel and Korea while it has dropped dramatically in Greece and Ireland.

Useful Links

World Health Organisation 

American Healthcare Association

The British Healthcare Business Intelligence Association

OECD, Health Policies and Data

Healthcare

Life Sciences

The Life Sciences industry includes biotechnology, healthcare, pharmaceuticals, medical devices and diagnostics. The industry is dominated by US companies requiring considerable investment in research and development to stay competitive.  While US companies dominate this space, competition is emerging from smaller companies in Europe and Asia. 

Companies trying to stay competitive or enter new markets in life sciences consult our reports. For example, Plimsoll, in their recent review of global antibiotic manufacturers have reviewed 150 of the largest manufacturers including analysis of  ANTIBIOTICE SA, BAYER HEALTHCARE MANUFACTURING SRL and CIPLA LTD. 

Our reports are a requirement for companies looking for the best competitive intelligence in the life sciences sector providing information on market size, rankings, best trading partners and financial analysis. 

Useful Links

Analytical Life Sciences and Diagnostics Association

German Life Sciences Association

 

Life Sciences

Industry

Industries

 

 

Buy: Epithelial Ovarian Cancer - Pipeline Review, H2 2016

 

Item Code: 05IB-GMDHC8712IDB

 
Licence: Single User
Price: $2000.00
 
VAT: 0.0% 
Total: $2000.00 

Feedback

Return to Research and Experts

Page created and rendered - Cache updated [1.36668s]

--